Meanwhile, the S&P BSE Sensex was down 30.91 points or 0.17% at 18,478.79.
On BSE, 6,810 shares were traded in the counter as against average daily volume of 30,370 shares in the past one quarter.
The stock hit a high of Rs 1,908.10 and a low of Rs 1,875 so far during the day. The stock had hit a record high of Rs 1,968.60 on 25 January 2013. The stock had hit a 52-week low of Rs 1,528 on 19 June 2012.
The stock had outperformed the market over the past one month till 4 April 2013, surging 7.16% compared with the Sensex's 1.95% fall. The scrip had also outperformed the market in past one quarter, rising 0.1% as against Sensex's 6.44% fall.
The large-cap company has equity capital of Rs 84.91 crore. Face value per share is Rs 5.
Shares of Dr. Reddy's Laboratories have risen 3.65% in two trading sessions from Rs 1,834.85 on 3 April 2013, after the company during trading hours on Thursday, 4 April 2013, said it has launched Zoledronic Acid Injection (5 mg/100 ml), therapeutic equivalent generic version of Reclast (Zoledronic acid) Injection 5 mg/100 ml in the US market on 3 April 2013, following the approval by the United States Food and Drug Administration (USFDA) of the company's abbreviated new drug application (ANDA) for Zoledronic Acid Injection (5 mg/100 ml). The stock had risen 3.02% to settle at Rs 1,890.40 on Thursday, 4 April 2013.
According to IMS Health data, the Reclast brand had annual sales of approximately $355 million in the United States for the twelve months ended February 2013, Dr. Reddy's said in a statement.
Dr. Reddy's Zoledronic Acid Injection (5 mg/100 ml) is available in a single use vial for intravenous infusion, Dr. Reddy's said in a statement.
Dr. Reddy's Laboratories' consolidated net profit declined 29.2% to Rs 363.31 crore on 3.5% growth in net sales to Rs 2865.16 crore in Q3 December 2012 over Q3 December 2011.
Dr. Reddy's Laboratories is an integrated global pharmaceutical company. Through its three businesses -- Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products -- Dr. Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars, differentiated formulations and NCEs. Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management, anti-infective and pediatrics. The company's major markets include India, USA, Russia and CIS, Germany, UK, Venezuela, S. Africa, Romania, and New Zealand
Powered by Capital Market - Live News
